

Table S3 - Utilities derived for cancer

Author, Year, Country	Study Design	Condition	Interventions	Setting	Mean (SD) Age	% Males	Utility Instrument	Baseline Utility		End of Study Utility	
								N	Mean (SD)	N	Mean (SD)
Children/Adolescents & Adults											
Alessi et al. 2007 Italy	cross-sectional	survivors of childhood cancer	n/a	postal questionnaire to cancer registry patients (n=644)	n/a; age >15	Range 30-73.7	HUI 3	Leukemia: 187 Non-Hodgkin lymphoma: 46 Hodgkin disease: 49 CNS tumours: 133 Neuroblastoma: 35 Retinoblastoma: 19 Wilms tumour: 42 Bone tumour: 31 Soft tissue sarcomas: 42 Gonadal tumours: 20 All other: 40	0.85 0.88 0.85 0.73 0.75 0.51 0.85 0.75 0.85 0.83 0.88	n/a	n/a
Cardarelli et al. 2006 Italy	cross-sectional	survivors of childhood cancer	n/a	previously treated patients (n=213)	13.3 (range 8-28)	52	HUI 2	Self assessment Brain tumours: 50 Leukemia/lymphoma: 89 Other solid tumours: 74 Overall population: 213	0.87 0.96 0.94 0.92	n/a	n/a
Felder-Puig et al. 2000 Germany	cross-sectional	survivors of childhood cancer	n/a	oncology outpatient department (n=142)	13 (range 6-30)	57.7	HUI 2	No sequelae Patients/parents: 74 Physicians: 76 Nurses: 88 Mild sequelae Patients/parents: 60 Physicians: 47 Nurses: 46 Moderate to severe sequelae Patients/parents: 8 Physicians: 19 Nurses: 8	0.94 (0.08) 0.97 (0.05) 0.96 (0.05) 0.88 (0.14) 0.95 (0.10) 0.93 (0.05) 0.80 (0.18) 0.78 (0.23) 0.64 (0.28)	n/a	n/a
Fluchel et al. 2008 Uruguay	cross-sectional	survivors of childhood cancer & age-matched controls	n/a	cancer registry	survivors: 13.6 (4.26) controls: 12.2 (2.7)	49.5 33.3	HUI 3	Brain tumour: 19 ALL survivors: 49 All survivors: 92 Controls: 96	0.601 (0.2399) 0.722 (0.2496) 0.661 (0.2625) 0.80 (0.1429)	n/a	n/a
Fu et al. 2006 6 countries in Central America	cross-sectional	survivors of childhood cancer	n/a	previously treated patients (n=211)	median: 12.8 (range 3-25)	56	HUI 2	All patients self-assessment: 165 All patients parent proxy: 140 All patients physician proxy: 201 ALL: 72 Hodgkin's disease: 28	0.872 (0.16) 0.90 (0.12) 0.94 (0.11) 0.871 (0.18) 0.858 (0.17)	n/a	n/a
							HUI 3	All patients self-assessment: 175 All patients parent proxy: 181 All patients physician proxy: 200 ALL: 76 Hodgkin's disease: 30	0.733 (0.27) 0.84 (0.2) 0.89 (0.19) 0.725 (0.30) 0.747 (0.24)	n/a	n/a
Kennedy et al. 1999 UK	cross-sectional	survivors of brain tumours	n/a	previously treated patients	median: 8.6 (range 2-19)	n/a	HUI 2	32	0.81 (0.178)	n/a	n/a
Pogany et al. 2006 Canada	cross-sectional	survivors of primary cancer before age 20 & general population controls	n/a	patients identified through national retrospective cohort study	n/a (range 5-37)	survivors: 51.2 controls: 48.4	HUI 3	survivors: 2152 controls: 2432	0.83 (0.21) 0.87 (0.17)	n/a	n/a
Schultz & Kopec 2003 Canada	cross-sectional	cancer	n/a	National health survey (n=73,402)	n/a (age ≥12)	49.2	HUI 3	Cancer: 1359	0.78	n/a	n/a

Shimoda et al. 2008 Brazil	cross-sectional	survivors of childhood cancer	n/a	previously treated patients	22.8 (range 13-40)	54	HUI 3	All patients: 138 ALL: 31 Hodgkin disease: 15 Non-hodgkin lymphoma: 13 Osteosarcoma: 15 Retinoblastoma: 18 Wilms tumour: 23 Germ cell tumour: 6 Other: 17	0.80 (0.263) 0.83 (0.225) 0.76 (0.215) 0.88 (0.164) 0.80 (0.259) 0.78 (0.324) 0.78 (0.283) 0.49 (0.462) 0.89 (0.189)	n/a	n/a
Shimoda et al. 2005 Brazil	cross-sectional	survivors of childhood cancer	n/a	previously treated patients	23.4 (5.51)	60	HUI 2	<u>Self-Assessment</u> All patients: 50 ALL: 8 <u>Physician Proxy</u> All patients: 50 <u>Nurse Proxy</u> All patients: 50 ALL patients: 8 Hodgkin's disease: 8 Wilms' tumour: 8	0.84 (0.178) 0.88 (0.19) 0.84 (0.166) 0.80 (0.158) 0.85 (0.16) 0.88 (0.08) 0.81 (0.12)		
							HUI 3	<u>Self-Assessment</u> All patients: 50 ALL: 8 Hodgkin's disease: 8 <u>Physician Proxy</u> All patients: 50 <u>Nurse Proxy</u> All patients: 50 ALL patients: 8 Hodgkin's disease: 8 Wilms' tumour: 8	0.78 (0.271) 0.85 (0.25) 0.80 (0.21) 0.74 (0.307) 0.73 (0.280) 0.85 (0.17) 0.80 (0.21) 0.76 (0.24)	n/a	n/a
Van Schaik et al. 1999 Canada	cross-sectional	survivors of childhood Hodgkin's disease	n/a	previously treated patients	median: 21.9	66.7	HUI 2	33	0.85 (0.13)	n/a	n/a
Children/Adolescents											
Barr et al. 1997 Canada	Non-randomized, prospective; 3 weeks	ALL	chemotherapy on ambulatory basis	hospital	median: 3 yrs 11 months (range 11 months - 14 years)	n/a	HUI 2	Parents proxy: 18 Physician proxy: 18 Nurse proxy: 18	0.86 (0.17) 0.90 (0.10) 0.96 (0.05)	18 18 18	0.89 (0.09) 0.89 (0.12) 0.91 (0.13)
Barr et al. 1999 Canada	cross-sectional	survivors of CNS tumours	n/a	neuro-oncology follow up clinic	9.5 (range 1-17)	50	HUI 2	Disease free: 28 Residual: 10 Recurrent: 3	0.89 (0.13) 0.81 (0.19) 0.56 (0.41)	n/a	n/a
							HUI 3	Disease free: 28 Residual: 10 Recurrent: 3	0.78 (0.26) 0.56 (0.26) 0.32 (0.57)	n/a	n/a
Barr et al. 2000 Canada	cross-sectional	survivors of Wilm's tumour or neuroblastoma	n/a	previously treated patients	Wilm's: 9.1 (3.35) Neuroblastoma: 7.8 (3.13)	50 31	HUI 2	Wilm's: 52 Neuroblastoma: 26	0.95 (0.08) 0.90 (0.13)	n/a	n/a
							HUI 3	Wilm's: 52 Neuroblastoma: 26	0.93 (0.12) 0.87 (0.19)	n/a	n/a
Cox et al. 2005 USA	Non-randomized, prospective; 31 weeks	ALL	institutional treatment protocol	hospital	median: 10 (range 6-18)	44.4	HUI 3	n/a	n/a	22	0.87 (SE=0.06)
Glaser et al. 1999 UK	cross-sectional	survivors of CNS tumours	n/a	previously treated patients	10.5 (range 6-16)	33.3	HUI 2	Survivors: 25 Parents: 26 Physicians: 23 Physiotherapist: 28	0.78 (0.18) 0.82 (0.18) 0.89 (0.11) 0.85 (0.13)	n/a	n/a
							HUI 3	Survivors: 26 Parents: 27 Physicians: 24 Physiotherapist: 28	0.66 (0.28) 0.72 (0.29) 0.83 (0.17) 0.76 (0.24)	n/a	n/a
Grant et al. 2006 Canada	cross-sectional	survivors of childhood cancer	n/a	previously treated patients	males: 17.55 (1.35) females: 17.81 (1.51)	50	HUI 2	All patients: 84 Males: 42 Females: 42	0.87 (0.14) 0.90 0.83	n/a	n/a

							HUI 3	All patients: 84 Males: 42 Females: 42	0.79 (0.23) 0.73 0.84	n/a	n/a
Hinds et al. 2007 USA	Non-randomized, prospective; 48 weeks	ALL	treatment protocol for ALL	pediatric oncology units	median: 8.6 (range 4-18)	66	HUI 3	n/a	n/a	24	0.91 (0.03)
Merchant et al. 2002 USA	cross-sectional	survivors of craniopharyngioma	n/a	previously treated patients	median: 8.6 (range 1-15)	44.8	HUI 2	<u>Initial Treatment</u> Surgery: 14 Limited surgery + radiotherapy: 15	0.716 0.85	n/a	n/a
Wright et al. 2003 Canada	cross-sectional	survivors of ALL & disease-free controls	n/a	previously treated patients	ALL: 12.1 (3.6) controls: 11.9 (2.9)	53.2 47.9	HUI 2	ALL: 62 Controls: 71	0.91 (0.084) 0.96 (0.057)	n/a	n/a
							HUI 3	ALL: 62 Controls: 71	0.86 (0.166) 0.96 (0.077)	n/a	n/a
Wright et al. 2005 Canada	cross-sectional	survivors of ALL	n/a	previously treated patients	survivors: 12.1 (4.9) controls: 12.2 (5.2)	55.6 49.4	HUI 3	survivors: 77 controls: 71	0.86 (0.18) 0.97 (0.08)	n/a	n/a
Yaris et al. 2001 Turkey	Non-randomized, non-comparative, prospective; 3 months	newly diagnosed cancer	treatment for cancer	n/a	9.7 (4.6)	53.3	HUI 2	30	0.81 (0.12)	30	0.85 (0.11)
Sung et al. 2003 Canada	cross-sectional	inpatients undergoing chemotherapy & non- oncology outpatients (controls)	n/a	Inpatients & outpatients	inpatients: 7.2 (4.0) controls: 10.1 (4.1)	64 43	HUI 2	inpatients: 36 controls: 49	0.85 (0.18) 0.80 (0.19)	n/a	n/a
							HUI 3	inpatients: 36 controls: 49	0.84 (0.23) 0.76 (0.24)	n/a	n/a
							SG	inpatients: 36 controls: 49	0.83 (0.29) 0.93 (0.12)	n/a	n/a
							TTO	inpatients: 36 controls: 49	0.64 (0.33) 0.88 (0.14)	n/a	n/a

SD-standard deviation; n/a-not available; CNS-central nervous system; ALL-acute lymphoblastic leukemia